1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma.
Saved in:
| Title: | 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma. |
|---|---|
| Authors: | Dummer, R.1 (AUTHOR), Flaherty, K.T.2 (AUTHOR), Robert, C.3 (AUTHOR), Arance, A.4 (AUTHOR), de Groot, J.W.B.5 (AUTHOR), Garbe, C.6 (AUTHOR), Gogas, H.J.7 (AUTHOR), Gutzmer, R.8 (AUTHOR), Krajsová, I.9 (AUTHOR), Liszkay, G.10 (AUTHOR), Loquai, C.11 (AUTHOR), Mandala, M.12 (AUTHOR), Schadendorf, D.13 (AUTHOR), Yamazaki, N.14 (AUTHOR), Zohren, F.15 (AUTHOR), Edwards, M.16 (AUTHOR), Ascierto, P.A.17 (AUTHOR) |
| Source: | Annals of Oncology. 2021 Supplement 5, Vol. 32, pS872-S873. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.08.1426 |
